REGN logo

Regeneron Pharmaceuticals, Inc.

REGN
Healthcare|Biotechnology|US
$904.35
+1.45 (+0.16%)
DCF Value
$2028.80
Tangible Book / Share
$316.45
Graham Number
$592.50
Cash / Share
$91.46

About

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.

Stock Price

+39.8%(1Y)
1M
+22.3%
3M
+15.3%
6M
+26.5%
YTD
+17.2%
1Y
+38.1%
3Y
+9.9%
5Y
+45.2%

Pipeline Summary

511 total trials
133
Phase 1
163
Phase 2
135
Phase 3
46
Phase 4
Completed: 264Active: 47Terminated: 48Recruiting: 102Withdrawn: 14Not Yet Recruiting: 15By Invitation: 1Available: 3Unknown: 9Approved: 5No Longer Available: 3

Active Trials (149)

Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
NCT04050436Cutaneous Squamous Cell Carcinoma
Phase 2Active
Enrollment: 231 participants
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
NCT04291105Melanoma
Phase 2Active
Enrollment: 87 participants
COPD Exacerbation Follow Up
NCT07118306COPD (Chronic Obstructive Pulmonary Disease)
Recruiting
Enrollment: 485 participants
Transformative Research in Diabetic Nephropathy 2.0
NCT07444203Diabetic Nephropathies
Recruiting
Enrollment: 200 participants
Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents
NCT05347771Asthma
Phase 2Active
Enrollment: 240 participants

BioScore

7.5/10
Buy

Key Facts

Market Cap$93.54B
Employees15,410 (+2% YoY)
CEOLeonard S. Schleifer
IPO DateApr 2, 1991
Beta0.24
52-Week Range$591.52 – $991.73
Avg Volume783,901
ExchangeNASDAQ

Ownership

Float96.2%
Shares Outstanding103.4M

Recent Insider Trades

Pitofsky JasonOPTION EX.
Nov 4, 2026905 shares @ $492.00
Pitofsky JasonSELL
Nov 4, 2026439 shares @ $939.57
Pitofsky JasonOPTION EX.
Nov 4, 20261,478 shares @ $644.54
Pitofsky JasonSELL
Nov 4, 2026575 shares @ $940.46
Pitofsky JasonSELL
Nov 4, 2026982 shares @ $941.58

Peers

AMGNAmgen Inc.
$248.92B
AZNAstraZeneca PLC
$289.14B
BIIBBiogen Inc.
$36.71B
EYPTEyePoint Pharmaceuticals, Inc.
$30.2M
GILDGilead Sciences, Inc.
$207.00B
GMABGenmab A/S
$32.98B
IVBXFInnovent Biologics, Inc.
$19.35B
NVSNovartis AG
$307.00B
Data last updated: Nov 9, 2026, 04:31 AM